



# Company presentation

---

January 2026

# Confidential – Do not duplicate or distribute without the written permission of Advanced Health Intelligence Ltd



This presentation ("Presentation") has been prepared by Advanced Health Intelligence Ltd ("Advanced Health Intelligence" or "Company").

You must read and accept the conditions in this notice before considering the information set out in or referred to in this Presentation. If you do not agree, accept or understand the terms on which this Presentation is supplied, or if you are subject to the laws of any jurisdiction in which it would be unlawful to receive this Presentation or which requires compliance with obligations that have not been complied with in respect of it, you must immediately return or destroy this Presentation and any other confidential information supplied to you by Advanced Health Intelligence. By accepting this document, you acknowledge and agree to the conditions in this notice and agree that you irrevocably release Advanced Health Intelligence from any claims you may have (presently or in the future) in connection with the provision or content of this Presentation.

## **NO OFFER**

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction (and will not be lodged with the ASIC).

This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire shares of Advanced Health Intelligence and does not and will not form any part of any contract for the acquisition of shares of Advanced Health Intelligence.

## **SUMMARY INFORMATION**

This Presentation contains summary information about Advanced Health Intelligence, its subsidiaries and their activities which is current as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Advanced Health Intelligence or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act. While Advanced Health Intelligence has taken every effort to ensure the accuracy of the material in the presentation, neither the Company nor its advisers have verified the accuracy or completeness of the information, or any statements and opinion contained in this Presentation.

## **NOT INVESTMENT ADVICE**

Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Advanced Health Intelligence and the impact that different future outcomes may have on Advanced Health Intelligence.

This Presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. Advanced Health Intelligence is not licensed to provide financial product advice in respect of Advanced Health Intelligence shares.

Cooling off rights do not apply to the acquisition of Advanced Health Intelligence shares.

## **INVESTMENT RISK**

An investment in Advanced Health Intelligence shares is subject to known and unknown risks, some of which are beyond the control of Advanced Health Intelligence. Advanced Health Intelligence does not guarantee any particular rate of return or the performance of Advanced Health Intelligence, nor does it guarantee any particular tax treatment. An investment in Advanced Health Intelligence should be considered as Highly Speculative and High Risk due to the start up nature of the Company and its proposed business.

## **FINANCIAL DATA**

All dollar values in this Presentation are in Australian dollars (A\$ or AUD) unless otherwise stated.

## **FORWARD-LOOKING STATEMENTS**

This Presentation may contain forward looking statements. The words 'anticipate', 'believe', 'expect', 'project', 'forecast', 'estimate', 'likely', 'intend', 'should', 'could', 'may', 'target', 'plan' and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements are subject to risk factors associated with the Company's business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements. You should not place undue reliance on forward-looking statements and neither Advanced Health Intelligence nor any of its directors, employees, advisers or agents assume any obligation to update such information.

## **DISCLAIMER**

None of Advanced Health Intelligence's respective advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, employees and agents, have authorized, permitted or caused the issue, submission, dispatch or provision of this Presentation and, except to the extent referred to in this Presentation, none of them makes or purports to make any statement in this Presentation and there is no statement in this Presentation which is based on any statement by any of them.

To the maximum extent permitted by law, Advanced Health Intelligence and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents exclude and disclaim all liability, including without limitation for negligence or for any expenses, losses, damages or costs incurred by you as a result of your participation in an investment in Advanced Health Intelligence and the information in this Presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise.

To the maximum extent permitted by law, Advanced Health Intelligence and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation.



## AHI Partners with His Excellency Dr. Obaid Alketbi and The Dr. O Group to Transform Healthcare Across the Middle East

We are proud to share AHI's strategic partnership with His Excellency Dr. Obaid Alketbi and The Dr. O Group a collaboration that reflects a shared commitment to redefining healthcare delivery throughout the Middle East.

His Excellency Dr. Obaid Alketbi widely known as Dr. O is a prominent and deeply respected figure in the UAE and across the globe. His distinguished career spans academia, diplomacy, and national service, including roles as UAE Ambassador, Military General, Chief of Logistics in the UAE Armed Forces, and Deputy Commander-in-Chief of Abu Dhabi Police.

A true embodiment of leadership and resilience, Dr. O's personal transformation toward health and wellness stands as a powerful testament to his character. Once allowing his own well-being to take second place to duty, he has since embraced a lifestyle of fitness and balance today, he is a dedicated marathon runner and advocate for the role of sport in promoting national identity, values, and diplomacy.

The founding of The Dr. O Group in February 2019 marked a new phase in his mission to give back to the nation that shaped him. The group supports both international and local brands that champion quality, authenticity, and wellness. The Dr. O Group is leading the UAE's transformation into a regional hub for health and well-being.

Museum 1185, located in Abu Dhabi, is a unique private museum founded by His Excellency Dr. Obaid Al Ketbi. Named after his military service number, the museum houses over 15,000 artifacts collected throughout his distinguished career in the UAE Armed Forces, diplomacy, and public service. The collection includes military memorabilia, diplomatic gifts, rare manuscripts, and cultural items from more than 160 countries, offering a personal narrative intertwined with the nation's history. Museum 1185 serves as an educational and inspirational space, reflecting the values of ambition, resilience, and national pride. Visits are available by reservation or invitation.

This vision aligns seamlessly with AHI's own mission to make healthy living simple, accessible, and driven by actionable insight. Together, we aim to empower individuals through knowledge, facilitate access to better health choices, and elevate the overall standard of well-being across the region.

This alliance is not just a partnership; it is a purposeful movement, guided by the vision and leadership of Dr. O. Through our joint efforts, we are committed to building a healthier, more vibrant UAE one where future generations thrive, and where health becomes a fundamental right, not a privilege.



# AHI is leveraging digital technology to revolutionise Cardio Metabolic Remote Patient Management and Monitoring



## Our mission

Provide accessible digital technology solutions to enhance human health



**Our vision** Ubiquitous proactive health care

## Empowering physicians, payers, patients and pharma to:

- **Increase access** to remote non-invasive and simple to conduct assessment of digital biomarkers, vital signs and associated risks
- **Predict likelihood of obesity driven chronic disease** for earlier, more personalized interventions
- **Provide insights** to support consultations, electronic health records, program development and policy-making
- **Save costs** for obesity and related cardiometabolic and liver disease and **enhance processes** and workflows (e.g. digital triaging)

## Using our established solutions to bridge from cardio-metabolic disease into a targeted platform for the obesity market

- Growth market with global drug of spend USD15 bn in 2024, potentially reaching USD150bn in 2035<sup>1</sup>
- Increasing acknowledgement of the importance of obesity in preventing cardiovascular and metabolic deaths
- Significant unmet need for long term, post GLP-1 solutions due to cost and side effects
- Diverse value drivers across physicians, payers (insurers and pharmacy benefit managers), patients and pharma

## Currently deployed in North America, the UK and Asia across life insurance, wellness, public health and medical records industries

*"AHI's technology is both unique and universally applicable. We identified what the healthcare system needed and, rather than reinventing the science, **we digitized it**"*

*Vlado Bosanac, AHI Founder*



1 - <https://www.morganstanley.com/insights/articles/weight-loss-medication-market-unstoppable-growth>

# AHI has dedicated 10 years of Science and Development with \$100m invested aimed at Cardio Metabolic Disease







# AHI's Money Shot: starting with an obesity remote patient care platform with a personalized digital health coach, companion and physician advisor

A digital-first, obesity cause-finding, learning and orchestration platform that journeys with the obesity patient and their primary care coordinator through smartphone sensing and clinical data, suggests routes to the right mix of digital tracks and specialist care, and learns outcome-to-phenotype mappings over time to continuously improve match quality and return on investment.

## Product and tech architecture



Software solutions



**Privacy First:** In-country hosting, federated learning across sites, differential privacy for analytics—fully compliant with HIPAA, GDPR and UAE data protection requirements.



**Where we are today**

# AHI Sensing and Data Stack offers patented remote digital Cardio Metabolic biomarker solutions primed for Obesity



Analyses **47 health markers** and **35 health risks** in <15 minutes, including obesity, diabetes, hypertension, cardiovascular disease, metabolic syndrome and mental health disorders  
**Sensor input modules validated in eight studies**




Analyses **vital signs** to predict 15 **health risks** in <2 minutes  
 Predicts risks related to weight, blood pressure, cholesterol, and cardiac profile  
**Validated in three studies:** All estimates met mean error hypotheses vs medical devices



Measures and analyses **body composition and dimension**  
 Predicts risk of obesity, metabolic syndrome and diabetes and enables progress tracking vs fitness goals – **FDA Registration Underway\***  
**Validated in three published studies:** R = 0.84-0.97



Detects **14 heart arrhythmias** including atrial fibrillation  
 Advanced heart rhythm monitoring for detection when arrhythmias occur, aiding diagnosis and management  
**Validated accuracy of 91% - 99% across ten studies and FDA cleared (K232804) with ECG equivalence**




^ Data processed on-device: no images or videos transmitted

\* In development



## We have 25 issued patents; with 45 pending or published



# We have a growing global partner base and will continue to ramp up Revenue whilst we commercialise the money shot



AHI is projected to continue its growth trajectory, with target revenue from existing solutions estimated at >\$25m by 2028



Solution live



Customer validation stage



Build in progress



**Obesity Market opportunity**

# Why obesity: \$1 trillion global problem with high unmet needs, fast growth and future potential

## Current market

- Growth market with global drug of spend USD15 bn in 2024, potentially reaching USD150bn in 2035<sup>1</sup>, driven by:
  - Recognition of obesity as a key factor in long term cardiovascular outcomes
  - Expanding regulatory indications for existing drugs
  - New drug classes becoming available (GLP-1-GIP combinations)
- Improved length and quality of life for people at risk of cardiovascular death
- Pharma has increased the obesity playing field by changing boundaries – eating into the wellness market spend

## Remaining unmet need / complications in addressing those

- There are still >1bn people living with obesity globally, with >30% prevalence in UAE and US
- Efficacy can plateau for certain patients after initial positive results, and patients can experience substantial weight regain after stopping drug treatment
- Intolerable side effects e.g. GI symptoms and high prices limiting accessibility
- Fragmented and uncoordinated provider systems in UAE and US
- Downstream organ systems derangement and other health effects of obesity

## Expectations for future potential


- Further growth in user volume, driven by price erosion / generic competition, increasing physician comfort and new/better drugs
- Obesity will be treated as a chronic disease for the masses requiring far more disease management and co-ordination across the health care system
- Refinement of the one size fits all approach, addressing cause and effects of obesity on a more individualised patient level<sup>2</sup>

<sup>1</sup> - <https://www.morganstanley.com/insights/articles/weight-loss-medication-market-unstoppable-growth>

<sup>2</sup> - <https://www.goldmansachs.com/insights/articles/the-anti-obesity-drug-market-may-prove-smaller-than-expected>

# Obesity is at the epi-centre for cardio metabolic disease leading to premature death

Causes of obesity and its association with increased cardiovascular risk factors according to the American College of Cardiology





# Obesity will increasingly become a chronic disease with active remote patient treatment approaches in large populations serviced by GLP1's


Perspective		
Patient	<ul style="list-style-type: none"><li>Actively driving their own health through self advocacy and increasingly equipped with the right information to ask the right questions</li></ul>	<ul style="list-style-type: none"><li>Driving their own care pathways with increasing influence over their providers and payers</li></ul>
Funding	<ul style="list-style-type: none"><li>Self pay or private payers</li></ul>	<ul style="list-style-type: none"><li>Public payers</li></ul>
Treatment guidelines	<ul style="list-style-type: none"><li>Drugs used short term, in part due to cost pressure</li></ul>	<ul style="list-style-type: none"><li>Drugs will be used as chronic treatment alongside lifestyle support</li></ul>
Provider	<ul style="list-style-type: none"><li>Time and financial pressures restrict a more holistic care approach</li></ul>	<ul style="list-style-type: none"><li>Decrease in fragmentation allows approaches that focus on the whole patient</li></ul>
Regulatory	<ul style="list-style-type: none"><li>GLP-1 drugs are approved, and safety is increasingly demonstrated</li></ul>	<ul style="list-style-type: none"><li>More and better availability of drug therapies, including combination molecules</li></ul>
Public Health Systems	<ul style="list-style-type: none"><li>Increasing focus on prevention, longevity and wellness</li></ul>	<ul style="list-style-type: none"><li>Next-level health care system prioritising wellness to support increasing longevity</li></ul>

# Guidelines from the American College of Cardiology recommend a multidisciplinary approach including drugs

## Multidisciplinary team approach for weight management



## Weight Loss Thresholds Associated With Comorbidity Improvements




## Playbook – AHI will tap into the existing money flow being unlocked by Big Pharma – multiple sources of income to be exploited



Stakeholder	Deployment	Payment model	Potential fees
<b>Pharma</b>	Companion diagnostic or R&D tool	Annual licence fee	\$millions annually
<b>Private health insurers</b>	Obesity managed care program with networks	Monthly program management fee per member (end-to-end) for managing the patients covered by certain policies	\$hundreds / member / month
<b>Independent physicians</b>	Helping to get the CPT code payment for managing obesity as a chronic disease – workflow automation	AHI takes percentage of CPT code payment in a revenue share model	\$10-20 per CPT code claim
<b>Provider groups</b>	Helping to get the CPT code payment for managing obesity as a chronic disease – work flow automation	AHI takes percentage of CPT code payment in a revenue share model	\$10-20 per CPT code claim

**As we scale, our revenue becomes more tightly coupled to value per patient: faster time to right care, sustained weight/comorbidity improvements, fewer avoidable complications, and lower friction for everyone in the ecosystem**

## Target markets include payer or provider segments in US, AsiaPac and UAE



**Geographies**

Characteristic		
Hospital based care coordination	✓	✓
High insured population	✓	✓
Need for efficiencies within high health care spend	✓	✓
Commitment to innovation	✓	✓
High unmet need	✓	✓

Potential roads to revenue include working with health insurers, pharma or health care providers. AHI will be exploring potential and risks of each stakeholder within Phase 1 of commercialization.

# Our leadership has 180+ years experience in relevant fields

## Board



**Nick Prosser,**  
*Chairman*

- 15+ years ICT experience.
- Founder of \$1.16 billion data centre exit in 2016



**Peter Goldstein,**  
*Independent Director*

- 30 years capital market, M&A , advisory experience
- Founder of exchange listing, LLC. CEO of Grandview Capital Partners, inc.



**Low Koon Low,**  
*Independent Director*

- 20 years accounting and corporate finance experience.
- Executive director SGX company.



**Mike Melby,**  
*Independent Director*

- Founder of fintech exit to phunware
- Investment banker and private equity investor



**Jacqueline Yee,**  
*Independent Director*

- 30 years institutional investor and global capital markets structured finance >\$25B
- Board directorships UK / APAC
- Funderbeam exchange CEO

## Key management



**Dylan Garnett,**  
*Chief Executive Officer*

- Expert in healthcare and biotech strategy
- Former COO Zurich Insurance and CEO Metropolitan Health Group



**Vlado Bosanac,**  
*Founder / Head of Strategy*

- Capital markets and investment banking in health tech expert
- Led four exits and co-founded AHI



**Simon Durack,**  
*Chief Financial Officer*

- 30+ years CPA
- 20+ years board experience
- Qualified Auditor



**Riaan Conradie, PhD,**  
*Chief Scientist*

- Expert in systems biology, electronics, mechanics, mathematics, physics and computer science
- Founder and former executive at LifeQ



**Prof. Manie de Klerk, MBChB, DCH, M Fam Med, MBA**  
*Clinical Director*

- Expert in medicine, health care delivery, med-tech, clinical trials and regulatory
- Former Head of Clinical Governance, Met, Health and GM of Product Development



# Thank-you

For more information on how Advanced Health Intelligence how our technologies can help you,  
email us at [hello@ahi.tech](mailto:hello@ahi.tech), or find out more at <https://ahi.tech>

*"We didn't create the science, we digitized it."*

**Vlado Bosanac , AHI Founder**



**Locations:**

**Asia Pacific:** Australia, Singapore

**South Africa:** Cape Town

**Europe:** Amsterdam

**UAE:** Dubai- Abu Dhabi

Email: [vlado@ahi.tech](mailto:vlado@ahi.tech)

AU: +61 412 000 409

UAE: +971 58 597 0090

# We will build out and scale the product as proof of value evolves

## Core principles

### Patient-first access

Patients do not pay out of pocket; access is funded by sponsors, providers, or insurers

### Ethical routing

We avoid pay-per-referral kickbacks; routing is based on fit, availability, and outcomes

### Value-based success

Our success is measured in time to right care and sustained outcomes, not in maximising drug or procedure volume

## Phase 1: Proof of orchestration

**Goal:** Prove we can diagnose "why" quickly, reduce time to right care, and show early improvements in weight, sleep, mood, and comorbid markers; obtain necessary certifications, automation of physician workflows

**Customer acquisition cost:** Near-zero; patients onboard via existing institutional channels

## Phase 3: Insurer per member per month and analytics

**New revenue:** US / UAE insurers per member per month for high-risk members; analytics/models/real world evidence for insurers and providers

**Contracts:** Link our upside to time to right care reduction and sustained outcomes, not simple cost cutting

**Existing streams:** Provider operating systems, network fees, cohorts, and white-label continue but become smaller share of total revenue

1

2

3

4

## Phase 2: Multi-provider operating systems and network effects

**Goal:** Turn pilots into a repeatable operating system across providers and cohorts; scale digital twin library and phenotyping

## Phase 4: Data flywheel and global scaling

**Goal:** Become the default operating system for obesity journeys across regions